SKU: 0676ATC

Jurkat, Clone E6-1 Human Blood Specialized Cells

Tumor Cell Lines > Leukemia Cell Lines

Product Type: Human Lymphocytes Cell Lines

Species: Human

Cell Type: Other / Specialized Cells

Source Organ: Blood

Inquire about this product

Delivery and Shipping

Ship on dry ice.

Cell Name: Jurkat, Clone E6-1

This is a clone of the Jurkat-FHCRC cell line, a derivative of the Jurkat cell line. The Jurkat cell line was established from the peripheral blood of a 14 year old boy by Schneider et al., And was originally designated JM.

  • Description
    Jurkat, Clone E6-1 is a human acute T-cell leukemia cell line originally established from the peripheral blood of a 14-year-old male patient with T-cell lymphoblastic leukemia. This suspension-growing lymphoblast-like cell line exhibits rapid proliferation. Cytogenetic analysis reveals a pseudodiploid karyotype (modal chromosome number 46) with recurrent abnormalities including deletions in chromosomes 2p21-p23 and 18p11.2, alongside mutations such as the TEL-JAK2 fusion gene and a frameshift mutation in Syk kinase that abolishes protein expression. The cells express CD3 surface markers and demonstrate interleukin-2 (IL-2) production. While primarily utilized for in vitro research, this cell line has been employed in subcutaneous xenograft models of leukemia.
  • Product Name
    Jurkat, Clone E6-1
  • Product Type
    Human Lymphocytes Cell Lines
  • Species
    Human
  • Source Organ
    Blood
  • Growth Conditions
    37 °C, 5% CO2
  • Application
    Jurkat, Clone E6-1 cells are used to investigate T-cell receptor signaling pathways, including CD3/CD28 co-stimulation and calcium-dependent NFAT activation. These cells serve as models for studying HIV latency mechanisms through engineered HIV-infected clones, enabling evaluation of viral reactivation and antiretroviral drug efficacy. The cell line is employed in preclinical screening of kinase inhibitors targeting JAK/STAT signaling abnormalities caused by TEL-JAK2 fusions. In immunotherapy development, Jurkat E6-1 derivatives modified with chimeric antigen receptors (CARs) test cytotoxic T-cell activation protocols. Xenograft models using this line assess leukemia progression in immunodeficient mice.
  • Size/Quantity
    1 vial
  • Recommended Medium And Supplement

    RPMI 1640 + 10% FBS
  • Shipping Conditions
    Dry Ice
  • Storage
    Liquid Nitrogen
  • Biosafety Level
    1

Payment & Security

Payment methods

    Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.

    Product inquiry

    Tell us what you need and our team will get back to you with pricing and availability.

    • Visit our support center

      Expert help & advice

    • Check your order status

      Updates & tracking

    • Returns & exchanges

      All you need to know

    • Price-match guarantee

      Our promise to you